Selegiline-transdermal--Somerset: Emsam.
D000279:Administration, Cutaneous; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003866:Depressive Disorder / Q000188:drug therapy; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D012642:Selegiline / Q000008:administration & dosage* / Q000009:adverse effects
D000978:Antiparkinson Agents; D015507:Drugs, Investigational; D012642:Selegiline